This article is more than 5 years old. Information may no longer be current.

Trial of squalamine combined with Lucentis fails to meet primary efficacy endpoint

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A trial of topically administered squalamine in combination with monthly Lucentis injections for wet age-related macular degeneration failed to meet its primary efficacy endpoint, according to a press release from Ohr Pharmaceutical.

The primary efficacy endpoint of the MAKO study was the mean visual acuity gain at 9 months.

The multicenter, randomized, double-masked, placebo-controlled clinical trial compared results of 237 patients. Those who received the combination of drugs were given topical squalamine lactate ophthalmic solution 0.2% twice daily as well as a monthly injection of Lucentis (ranibizumab, Genentech). The control group received a topical placebo twice a day and the Lucentis injection.

Patients who received the combination achieved a mean gain of 8.33 letters, while those who received Lucentis alone had a mean gain of 10.58 letters, the release said.